Beyond Air, Inc. (XAIR) Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. Its headquarters are situated in Garden City, New York.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
Beyond Air, Inc. NASDAQ:XAIR Healthcare · Medical - Devices
Mkt Cap $2.21M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended September 30, 2026
Beyond Air (NASDAQ: XAIR) will report financial results for the quarter ended September 30, 2026 on Wednesday, November 11, 2026.
Management will host a conference call and webcast at 4:30 p.m. ET the same day, with a replay available afterward on the company's website.
This is a scheduling notice only — no financial results, guidance, or operational updates are included.
• 3d ago AI analysis › Press Release ⚠ 3
Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026
Beyond Air preannounced preliminary unaudited revenue of approximately $2.3 million for the quarter ended September 30, 2026 — its highest quarterly revenue to date, up roughly 30% sequentially and 27% year over year.
Growth reflects continued hospital adoption of the first-generation LungFit PH nitric oxide delivery system, while the second-generation system remains under FDA review via a PMA supplement.
The company reaffirmed revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027, with the higher 2027 figure contingent on FDA approval of the second-generation system. Complete results will be reported in November 2026.
• 24d ago AI analysis › Press Release
Beyond Air to Participate in the 2026 Cantor Global Healthcare Conference
Beyond Air (NASDAQ: XAIR) announced that its management team will participate in the 2026 Cantor Global Healthcare Conference, held September 9-11, 2026 at the Waldorf Astoria New York.
The company's fireside chat is scheduled for Thursday, September 10 at 3:55 PM EDT, with a live webcast and a 90-day replay available on Beyond Air's website.
This is a routine investor-relations scheduling notice with no new financial, clinical, or regulatory information disclosed.
• 1mo ago AI analysis › Press Release ● Major
Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)
Beyond Air received FDA Breakthrough Device Designation for LungFit GO for the treatment of nontuberculous mycobacterial pulmonary disease (NTM-PD), a rare and serious chronic lung infection.
The designation is supported by pilot study data demonstrating that adult subjects could safely self-administer high-dose intermittent inhaled nitric oxide therapy at home with high compliance.
Management plans to leverage the Breakthrough Device Program to finalize the design of a future clinical study for LungFit GO in NTM-PD, potentially streamlining the regulatory review process.
• 2mo ago AI analysis › Press Release ⚠ 2
Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments
Beyond Air has agreed to sell its 58% stake in NeuroNOS Israel to UNIVO Pharmaceutical Industries, receiving a 19.99% equity stake in UNIVO and warrants upon closing.
The deal includes up to $32.5 million in potential milestone payments for Beyond Air, split between $6.5 million for development milestones and $26 million tied to commercial sales thresholds.
This transaction allows Beyond Air to focus its resources on the continued growth of its core LungFit business while maintaining alignment with NeuroNOS as a shareholder.
• 2mo ago AI analysis › Press Release ⚠ 2
Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update
Beyond Air reported Q2 revenue of $1.8 million, flat compared to the prior year, while gross margins improved to 13%.
The company secured up to $30.1 million in financing to support its commercial launch, consisting of $10.2 million in upfront proceeds and additional warrant exercises.
Management reaffirmed full-year 2026 guidance of $8 million and 2027 guidance of $16-$18 million, backed by a new group purchasing agreement covering nearly 2,000 U.S. hospitals.
• 2mo ago AI analysis › Press Release
Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended June 30, 2026
Beyond Air announced it will report financial results for the quarter ended June 30, 2026, on Thursday, August 13, 2026.
Management is scheduled to host a conference call and webcast at 8:00 a.m. Eastern Time to discuss the quarterly performance.
The company is a commercial-stage medical device and biopharmaceutical firm focused on nitric oxide therapies for respiratory illnesses and neurological disorders.
• 2mo ago AI analysis › Press Release ⚠ 2
Beyond Air® Announces Up to $30.1 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules
Beyond Air announced a private placement offering to raise up to $30.1 million in gross proceeds, selling shares and pre-funded warrants at a price of approximately $5.66 per share.
The financing includes the issuance of Series A and Series B warrants with an exercise price of $5.51, with proceeds intended to fund the commercial launch of LungFit PH and for general corporate purposes.
Cantor is acting as lead placement agent, with Citizens Capital Markets and Lake Street also participating in the offering.
• 3mo ago AI analysis › Press Release ● Major ⚠ 2
Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update
Beyond Air reported fiscal 2026 revenue of $7.7 million, up 107% year-over-year, driven by strong demand for its LungFit PH system in the U.S. and international markets. The company also issued guidance for calendar year 2027 of $16 to $18 million, representing more than 110% growth, anticipating the commercial launch of its second-generation LungFit PH system.
Management announced a corporate restructuring of its fiscal year-end to December 31 and appointed new leadership, including Robert Goodman as CEO. Despite the strong commercial progress, the board approved a 1-for-20 reverse stock split to regain compliance with Nasdaq listing requirements following a recent delisting risk warning.
Financial results showed a net loss per share of $(4.01) for the full year, while the company continues to burn cash at a rate of $19.1 million annually against a cash position of $17.3 million.
• 4mo ago AI analysis › Press Release
Beyond Air Schedules Fiscal Year End 2026 Financial Results Conference Call and Webcast
Beyond Air announced it will report fiscal fourth quarter and full-year 2026 financial results on Friday, June 26, 2026.
Management is scheduled to host a conference call and webcast at 8:00 a.m. ET on the same day to discuss the results.
The company is a commercial-stage medical device and biopharmaceutical firm focused on nitric oxide therapies, having received FDA approval for its LungFit PH system.
• 4mo ago AI analysis › Press Release
Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing
globenewswire.com • 5mo ago Press Release
Beyond Air to Participate in the D. Boral Capital Global Conference 2026
globenewswire.com • 6mo ago 
